Northrop Grumman Corporation vs Zoetis Inc — how do they compare? Northrop Grumman Corporation trades at $575 (market cap $81.78B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Northrop Grumman Corporation is far larger — about 2.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| NOC | ZTS | |
|---|---|---|
Market Cap | $81.78B | $31.14B |
Sector | Industrials | Health |
52-Week High | $768.02 | $156.76 |
52-Week Low | $496.02 | $71.91 |
Enterprise Value | $95.77B | $38.70B |
Dividend Yield | 1.63% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $577.11, down 0.13% on the day, with a bullish technical trend supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with a record $105 billion backlog, driven by defense contracts like the Sentinel program. Fundamentals show solid profitability with a 10.48% net income margin and 26.96% ROE, though valuation ratios like P/E of 18.3 are moderate. Recent news highlights a $3 billion missile-interceptor agreement, reinforcing growth prospects.
Outlook remains positive with analyst consensus favoring Buy (57% of ratings) and a $598.57 price target, implying ~4% upside. Key opportunities include sustained defense spending and backlog execution, while risks involve margin pressures from specific programs and geopolitical dependencies. The stock's proximity to its 52-week high suggests cautious optimism amid robust operational performance.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Latest headlines on both assets
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →